InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
16,867.60
(
-0.80%
)
Dow Jones
38,460.92
(
-0.11%
)
Brent Oil
87.30
(
0.09%
)
Bitcoin
64,120.00
(
-0.25%
)
Post# of 160314
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

jaybird249

Send PM Follow Ignore
Followers 82
Posts 2822
Boards Moderated 0
Alias Born 05/05/2006

jaybird249

Re: None

Wednesday, 10/05/2011 12:03:53 AM

Wednesday, October 05, 2011 12:03:53 AM

Post# of 160314
PATH is next TSPT
I bought TSPT at $2.8 I have also been loading on PATH.
There are lots of similarities.

Low float with lots of cash and traded near $10 earlier in the year.

Very effective treatments for a large market medical need.

Both had FDA rejections not because of effecacy, but safety issues.

PATH released a PR a few days ago that addresses the safety issue. If they get approval for the NDA resubmission PATH could be $5 in a hurry.

"This CRL gives us confidence that we can provide the information needed to support FDA approval for our migraine patch in a timely manner,"

"The Company believes that the complete data set for NP101-009 will be supportive of the resubmission of its NDA to the FDA."


Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up